RxDoctor Payments Data

Mohamed Rahman, MD

Clinical Cardiac Electrophysiology · Sherman, TXNPI 1932121571

Payments from drug & device makers

$9,545in general payments, 2019–2025

Across 161 payments — averaging $59.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$2K
  • Cvrx, Inc.$1K
  • Medical Device Business Services, Inc.$788
  • Abbott$675
  • Merck$485
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$200%
  • Travel & lodging$5,11954%
  • Food & beverage$4,39446%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,545 in reported general payments places this provider in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$935,138
Medicare patients
970
Services billed
9,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$297,792
FarxigaDapagliflozin Propanediol212$165,929
EntrestoSacubitril/Valsartan139$125,635
MultaqDronedarone Hcl93$78,590
XareltoRivaroxaban77$54,763
JardianceEmpagliflozin28$24,145
VerquvoVericiguat22$18,956
CorlanorIvabradine Hcl24$17,862
OzempicSemaglutide13$13,440
Clonidine98$8,656
Midodrine Hcl98$8,591
Ivabradine Hcl23$7,658
Ranolazine ErRanolazine104$5,214
Metoprolol Succinate639$5,044
Disopyramide Phosphate16$4,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$111$297,792353 claims
AstraZenecaFarxiga$40$165,929212 claims
NovartisEntresto$55$125,635139 claims
Sanofi-aventis U.S. LLCMultaq$63$78,59093 claims
Johnson & JohnsonXarelto$44$54,76377 claims
Boehringer IngelheimJardiance$23$24,14528 claims
MerckVerquvo$485$18,95622 claims
AmgenCorlanor$15$17,86224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →